One of the more logical strategies for treating diabetes-induced retinal neurodegeneration is ‘replacement’ treatment of the neurotrophic factors that are downregulated in the early stages of diabetic retinopathy, such as pigment epithelial derived factor, somatostatin and glucagon-like peptide 1 [3]. The gene discussed is SST; the disease is diabetes mellitus.